CTLA4 and neoplasm: Duraiswamy et al. (2013) confirmed in preclinical studies that combination therapy of the tumor cell vaccine along with a blockade of programmed cell death protein 1 (PD-1) and/or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) could improve tumor control [36].